Gonadotropin Salgılayan Hormon Analogları
Özet
Gonadotropin salgılayan hormon (GnRH) analogları, üreme sistemini düzenleyen lüteinleştirici hormon (LH) ve folikül stimulan hormon (FSH) sentezini kontrol eden hipotalamik-hipofiz-gonadal aks üzerinden etki gösteren sentetik ajanlardır. Doğal GnRH'ye kıyasla daha yüksek reseptör afinitesine ve enzimatik dirence sahip olan bu analoglar, sürekli maruziyet durumunda hipofiz reseptörlerinde downregülasyona yol açarak gonadal steroid sentezini baskılar. Klinik alanda puberte prekoks, infertilite, endometriozis ve uterin leiomyoma gibi benign durumların tanı ve tedavisinde yaygın olarak tercih edilirler. Onkolojide ise hormona duyarlı premenopozal meme kanseri ve ileri evre prostat kanserinde endokrin tedavinin temel taşını oluştururlar; meme kanserinde over fonksiyonlarını baskılayarak östrojen düzeyini azaltırken, prostat kanserinde medikal kastrasyon sağlayarak tümör büyümesini inhibe ederler. Uzun süreli kullanımları gonadal steroidogenez baskılanmasına bağlı olarak her iki cinsiyette de sıcak basması, libido azalması ve kemik mineral yoğunluğunda azalma gibi menopozal veya androjen eksikliği semptomlarına yol açtığından, tedavi sürecinde kemik dansitometrisi ve ilgili yan etkilerin takibi ile yönetimi klinik açıdan büyük önem taşımaktadır.
Gonadotropin-releasing hormone (GnRH) analogs are synthetic agents that act through the hypothalamic-pituitary-gonadal axis, controlling the synthesis of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which regulate the reproductive system. Possessing higher receptor affinity and enzymatic resistance compared to natural GnRH, continuous exposure to these analogs leads to downregulation of pituitary receptors, thereby suppressing gonadal steroidogenesis. In the clinical field, they are widely preferred for the diagnosis and treatment of benign conditions such as precocious puberty, infertility, endometriosis, and uterine leiomyoma. In oncology, they constitute the cornerstone of endocrine therapy in hormone-sensitive premenopausal breast cancer and advanced prostate cancer; they decrease estrogen levels by suppressing ovarian function in breast cancer and inhibit tumor growth by providing medical castration in prostate cancer. Since their long-term use leads to menopausal or androgen deficiency symptoms due to the suppression of gonadal steroidogenesis, such as hot flashes, decreased libido, and reduced bone mineral density in both sexes, the monitoring and management of related side effects alongside bone densitometry carry clinical significance during the treatment process.
Referanslar
Gilman AG. THE PHARMACOLOGICAL BASIS OF THERAPEUTICS: McGraw-Hill Education; 2018.
Katzung BG. Basic & Clinical Pharmacology. McGraw-Hill Education2018.
Davidson NE. Ovarian ablation as treatment for young women with breast cancer. Journal of the National Cancer Institute Monographs. 1994(16):95-9.
Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. Journal of the National Cancer Institute. 2009;101(5):341-9.
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. The New England journal of medicine. 2015;372(5):436-46.
Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, et al. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(19):2221-31.
Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast cancer research and treatment. 2011;126(2):443-51.
Rossi L, Pagani O. The role of gonadotropin-releasing-hormone analogues in the treatment of breast cancer. Journal of Women's Health. 2018;27(4):466-75.
Zong X, Yu Y, Yang H, Chen W, Ding X, Liu S, et al. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial. JAMA oncology. 2022;8(2):252-8.
Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. The Lancet Oncology. 2012;13(4):345-52.
Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, et al. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(14):1594-600.
Zagouri F, Sergentanis TN, Azim HA, Jr., Chrysikos D, Dimopoulos MA, Psaltopoulou T. Aromatase inhibitors in male breast cancer: a pooled analysis. Breast cancer research and treatment. 2015;151(1):141-7.
Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. Journal of hematology & oncology. 2015;8:53.
Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Annals of internal medicine. 2000;132(7):566-77.
Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. European urology. 2021;79(1):44-53.
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European urology. 2021;79(2):263-82.
Brunton LL, Hilal-Dandan R, Knollmann BC. THE PHARMACOLOGICAL BASIS OF THERAPEUTICS. Claudine Isaacs AW, and Anna T. Riege, editor: McGraw-Hill Education; 2018.
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. New England Journal of Medicine. 2013;368(14):1314-25.
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. The New England journal of medicine. 2016;375(15):1425-37.
Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(19):2143-50.
Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. The Lancet Oncology. 2019;20(12):1740-9.
Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA oncology. 2016;2(4):500-7.
